Residency · Residency · Gastroenterology

Hepatitis B - Natural History and Treatment

Virology

Hepatitis B virus belongs to the Hepadnaviridae family and is a partially double-stranded DNA virus with a compact 3.2 kilobase genome. Its replication strategy is unique among DNA viruses: genomic DNA is first transcribed into pregenomic RNA, which then undergoes reverse transcription back to DNA. This reverse transcriptase step is the molecular target of nucleos(t)ide analogue therapy.

Covalently closed circular DNA (cccDNA) is a stable minichromosome that persists within the hepatocyte nucleus and serves as the template for all viral transcripts. Critically, cccDNA persists despite serologic clearance and is not eliminated by any currently available antiviral therapy, providing the molecular basis for reactivation risk. In addition, integration of HBV DNA into the host genome occurs early in infection and represents a source of HBsAg production that is independent of cccDNA. This integration also contributes to hepatocarcinogenesis.

There are 10 major genotypes (A through J) with clinical significance: genotypes A and B demonstrate better response to interferon therapy, genotype C is associated with higher hepatocellular carcinoma risk, and genotype D is common in Mediterranean and Middle Eastern populations.

Serologic Markers

Hepatitis B surface antigen (HBsAg) is the marker of active infection, and its persistence for more than 6 months defines chronic hepatitis B. Anti-HBs, the antibody to surface antigen, indicates immunity, whether from vaccination or resolved infection, with a level of 10 mIU/mL or greater considered protective. Hepatitis B e antigen (HBeAg) is a marker of high viral replication and correlates with infectivity. Anti-HBe indicates seroconversion and lower replication, though HBV DNA may still be detectable in HBeAg-negative hepatitis. Anti-HBc IgM is a marker of acute infection, while anti-HBc IgG (total anti-HBc) indicates prior infection and is the key marker distinguishing vaccine immunity (anti-HBs alone) from natural immunity (anti-HBs plus anti-HBc). HBV DNA quantification is the most important marker for treatment decisions and monitoring. Quantitative HBsAg is an emerging biomarker whose levels correlate with cccDNA activity, and a decline during treatment predicts functional cure.

Serologic Patterns

The characteristic serologic patterns in hepatitis B include acute infection (HBsAg positive, anti-HBs negative, anti-HBc IgM positive, HBeAg positive or negative), chronic infection (HBsAg positive, anti-HBs negative, anti-HBc IgG positive, HBeAg positive or negative), resolved infection with immunity (HBsAg negative, anti-HBs positive, anti-HBc positive, HBeAg negative), vaccine immunity (HBsAg negative, anti-HBs positive, anti-HBc negative, HBeAg negative), and isolated anti-HBc (HBsAg negative, anti-HBs negative, anti-HBc positive), which may represent a window period, occult HBV infection, or a false-positive result.

Natural History Phases (AASLD 2018 Nomenclature)

Phase 1: HBeAg-Positive Chronic HBV Infection (Immune Tolerant)

Phase 1 is characterized by positive HBsAg, positive HBeAg, very high HBV DNA (exceeding 10 million IU/mL), normal ALT, and minimal hepatic fibrosis. This phase is common in perinatally infected individuals and can persist for decades. Patients are highly infectious but at low immediate risk of liver injury, though prolonged viremia increases long-term hepatocellular carcinoma risk. Treatment is generally not indicated, although evolving evidence suggests that treatment may reduce long-term HCC risk. Monitoring should occur every 6 to 12 months.

Phase 2: HBeAg-Positive Chronic Hepatitis B (Immune Active)

Phase 2 is defined by positive HBsAg, positive HBeAg, elevated HBV DNA (exceeding 20,000 IU/mL), elevated ALT, and active inflammation with or without fibrosis. Active immune-mediated hepatocyte destruction characterizes this phase, and treatment is indicated.

Phase 3: HBeAg-Negative Chronic HBV Infection (Inactive Carrier)

Phase 3 presents with positive HBsAg, negative HBeAg, positive anti-HBe, low HBV DNA (below 2000 IU/mL), and normal ALT. This phase carries a low risk of progression, with an annual HCC risk of 0.02 to 0.2%. Patients should be monitored every 6 to 12 months and may progress to phase 4 (reactivation).

Phase 4: HBeAg-Negative Chronic Hepatitis B (Reactivation)

Phase 4 is characterized by positive HBsAg, negative HBeAg, positive anti-HBe, fluctuating or elevated HBV DNA (exceeding 2000 IU/mL), and elevated ALT. This phase results from precore or basal core promoter mutant virus and carries a higher risk of progression to cirrhosis. Treatment is indicated.

Phase 5: HBsAg-Negative (Resolved/Occult HBV)

Phase 5 presents with negative HBsAg, positive anti-HBc, positive or negative anti-HBs, and undetectable or very low serum HBV DNA. Despite apparent resolution, cccDNA persists in hepatocytes, and there is a risk of reactivation with profound immunosuppression, particularly with anti-CD20 therapy and hematopoietic stem cell transplantation.

<image>A timeline infographic showing the five phases of chronic hepatitis B natural history. Display a horizontal timeline from left to right representing years to decades after perinatal infection. For each phase, show parallel graphs of: HBV DNA level (log scale, high to low), ALT level (with ULN marked), and liver histology (cartoon liver progressing from normal to inflamed to fibrotic). Phase 1 "Immune Tolerant": very high HBV DNA (>10^7), normal ALT, normal liver. Phase 2 "Immune Active (HBeAg+)": high HBV DNA with decline, elevated/fluctuating ALT, active hepatitis. Transition: "HBeAg seroconversion" (star marker). Phase 3 "Inactive Carrier": low HBV DNA (<2000), normal ALT, minimal fibrosis. Phase 4 "Reactivation (HBeAg-)": moderate HBV DNA with fluctuations, elevated ALT, progressive fibrosis. Phase 5 "HBsAg Loss": undetectable HBV DNA, normal ALT, residual fibrosis. Below the timeline, show HBeAg status bar (positive phases 1-2, negative phases 3-5) and HBsAg status bar (positive phases 1-4, negative phase 5). Mark treatment indication windows with green highlight (phases 2 and 4). Include HCC risk estimation at each phase. Use color gradients: red for active disease phases, green for quiescent phases.</image>

Treatment Indications (AASLD 2018)

Definite Treatment Indications

Definite indications for antiviral therapy include HBeAg-positive patients with HBV DNA exceeding 20,000 IU/mL and ALT greater than twice the upper limit of normal, HBeAg-negative patients with HBV DNA exceeding 2000 IU/mL and ALT greater than twice the upper limit of normal, cirrhosis with any detectable level of HBV DNA, HBV reactivation during immunosuppression, acute liver failure from HBV, and HBV-associated extrahepatic manifestations such as polyarteritis nodosa and glomerulonephritis.

Consider Treatment

Treatment should be considered for patients with ALT between 1 and 2 times the upper limit of normal who have significant fibrosis (F2 or greater) on biopsy or elastography, patients over age 40 with HBV DNA exceeding 2000 IU/mL and borderline ALT (for whom liver biopsy or elastography may be warranted to assess fibrosis), and those with a family history of hepatocellular carcinoma. Expanding indications, particularly in the EASL approach, now support treating all HBeAg-positive patients with HBV DNA exceeding 20,000 IU/mL regardless of ALT.

Monitoring Without Treatment

For HBeAg-positive patients in the immune tolerant phase, ALT should be checked every 3 to 6 months and HBV DNA every 6 to 12 months, with HCC screening as indicated. Inactive carriers should be monitored with ALT and HBV DNA every 6 to 12 months.

Treatment Options

Nucleos(t)ide Analogues (NUCs) — Preferred First-Line

Entecavir (ETV)

Entecavir is administered at 0.5 mg daily (1 mg for lamivudine-experienced patients). It possesses a high genetic barrier to resistance, with resistance rates below 1.2% at 6 years in treatment-naive patients. Dose adjustment is required for renal impairment (creatinine clearance below 50). While classified as FDA Category C, extensive safety data support its use, although tenofovir disoproxil fumarate is preferred in pregnancy.

Tenofovir Disoproxil Fumarate (TDF)

Tenofovir disoproxil fumarate is administered at 300 mg daily and has no documented resistance, possessing the highest genetic barrier among all nucleos(t)ide analogues. Renal toxicity, including Fanconi syndrome and nephrotoxicity, requires monitoring of creatinine and phosphate, and the drug should be avoided in chronic kidney disease. Bone mineral density loss of 1 to 2% may occur, and DEXA scanning is recommended for at-risk patients. TDF is preferred in pregnancy (FDA Category B) with extensive safety data. A switch to TAF should be considered if renal or bone concerns emerge.

Tenofovir Alafenamide (TAF)

Tenofovir alafenamide is administered at 25 mg daily. As a prodrug, it achieves lower plasma tenofovir levels than TDF, resulting in less renal and bone toxicity while maintaining non-inferior efficacy for HBV DNA suppression and ALT normalization. TAF is not recommended in decompensated cirrhosis due to limited data; entecavir or TDF should be used in that setting. Weight gain is an emerging concern, similar to observations with TAF in HIV. TAF is recommended over TDF for patients older than 60, those with chronic kidney disease or osteoporosis, and those receiving nephrotoxic agents.

Pegylated Interferon Alfa-2a (PEG-IFN)

Pegylated interferon alfa-2a is administered at 180 mcg subcutaneously weekly for a finite 48-week course. Its mechanism is both immunomodulatory and directly antiviral. Advantages include finite treatment duration, higher HBsAg loss rates (3 to 8% at 1 year), and no development of resistance. Disadvantages include significant side effects (flu-like symptoms, cytopenias, depression, and autoimmune phenomena), the need for close monitoring, and contraindications in decompensated cirrhosis and pregnancy. The best candidates are patients with genotype A, younger patients, those with low HBV DNA, high ALT, and no cirrhosis. Stopping rules guide treatment decisions: an HBsAg decline of more than 1 log at 12 weeks predicts response, while the absence of decline at 12 to 24 weeks suggests stopping therapy should be considered.

Treatment Endpoints

The primary goal of therapy is sustained suppression of HBV DNA to undetectable levels (below 10 to 20 IU/mL). HBeAg seroconversion, defined as loss of HBeAg with development of anti-HBe, allows consideration of NUC discontinuation, though relapse is common. HBsAg loss (functional cure) is the ultimate treatment goal and is achieved in fewer than 5% of patients on NUCs at 5 years and in 3 to 8% on pegylated interferon at 1 year. NUC discontinuation may be considered in selected non-cirrhotic HBeAg-negative patients after 3 or more years of viral suppression with an HBsAg level below 100 IU/mL and close monitoring; the RETRACT study showed that finite NUC therapy triggered HBsAg loss in some patients, although this approach remains controversial.

HBV Reactivation

High-Risk Immunosuppressive Agents

Anti-CD20 therapy (rituximab) carries the highest reactivation risk (exceeding 10%) and can cause fatal reactivation even in HBsAg-negative, anti-HBc-positive patients. Hematopoietic stem cell transplantation and high-dose chemotherapy also pose high risk. Anti-TNF agents carry moderate risk, with prophylaxis indicated for HBsAg-positive patients and monitoring recommended for anti-HBc-positive patients. Corticosteroids at a dose of 20 mg prednisone equivalent or more for 4 or more weeks represent a moderate risk. JAK inhibitors and checkpoint inhibitors have emerging risk data.

Prevention

All patients should be screened for HBsAg, anti-HBs, and anti-HBc before initiation of immunosuppressive therapy. HBsAg-positive patients require antiviral prophylaxis with entecavir or TDF starting before immunosuppression and continuing for at least 6 to 12 months afterward. HBsAg-negative, anti-HBc-positive patients receiving high-risk therapy (anti-CD20 or HSCT) should receive antiviral prophylaxis or undergo close monitoring with HBV DNA every 1 to 3 months, with prophylaxis preferred. HBsAg-negative, anti-HBc-positive patients receiving moderate-risk therapy should be monitored with HBV DNA and treated if viral load becomes detectable.

HCC Screening in HBV

HCC screening is indicated for all HBsAg-positive patients with cirrhosis, HBsAg-positive Asian males over 40 and Asian females over 50, HBsAg-positive African and African-American patients over 20, anyone with HBV and a family history of hepatocellular carcinoma, and HBsAg-positive patients with significant fibrosis. Screening consists of ultrasound with or without alpha-fetoprotein every 6 months. The PAGE-B score, incorporating age, sex, and platelet count, has been validated in Caucasian patients on NUC therapy, with a low-risk score (0 to 9) corresponding to an HCC incidence below 1% at 5 years, potentially allowing consideration of less intensive screening.

<image>A comprehensive HBV management algorithm. Start with "HBsAg positive confirmed." First tier: "Assess phase" with serologic workup (HBeAg, anti-HBe, HBV DNA quantitative, ALT, assess fibrosis). Branch into four management pathways: (1) "Immune tolerant (HBeAg+, very high DNA, normal ALT)" -> "Monitor ALT q3-6 months; HCC screening if indicated; treat if ALT elevates." (2) "Immune active HBeAg+ (DNA >20,000, ALT >2x ULN)" -> "TREAT: first-line ETV, TDF, or TAF; or consider PEG-IFN if genotype A, good candidate." (3) "Inactive carrier (HBeAg-, DNA <2000, normal ALT)" -> "Monitor ALT/DNA q6-12 months; HCC screening if indicated." (4) "HBeAg-negative hepatitis (DNA >2000, elevated ALT)" -> "TREAT: first-line ETV, TDF, or TAF (usually long-term/indefinite)." Side pathway: "Cirrhosis with ANY detectable HBV DNA" -> "TREAT indefinitely + HCC screening q6 months." Include a medication comparison box: ETV (0.5 mg, high barrier, renal adjust), TDF (300 mg, no resistance, renal/bone concerns, pregnancy safe), TAF (25 mg, less renal/bone, not for decompensated), PEG-IFN (48 weeks, finite, higher HBsAg loss). Use green for monitoring, red for treatment indication, blue for screening recommendations.</image>

Emerging Therapies and Functional Cure

Novel Targets Under Investigation

RNA interference (siRNA) therapies target HBV mRNA to reduce HBsAg production. Examples include bepirovirsen, an antisense oligonucleotide, and JNJ-3989, a small interfering RNA. Capsid assembly modulators disrupt nucleocapsid formation and interfere with cccDNA replenishment. HBsAg release inhibitors, or nucleic acid polymers (REP 2139, REP 2165), represent another novel approach. CccDNA targeting through CRISPR-based and epigenetic silencing strategies remains in the preclinical stage. Immunomodulatory approaches under investigation include therapeutic vaccines, TLR agonists (selgantolimod), checkpoint inhibitors, and engineered T cells. Combination strategies using a NUC backbone with siRNA, nucleic acid polymers, or immunomodulators represent the most promising path toward achieving functional cure, defined as HBsAg loss with sustained HBV DNA suppression off therapy.

Key Clinical Pearls

• cccDNA persists in hepatocytes even after HBsAg loss — basis for reactivation risk with immunosuppression and rationale for screening all patients before immunotherapy
• Screen ALL patients before immunosuppression with HBsAg, anti-HBs, anti-HBc — fatal reactivation is preventable
• Entecavir, TDF, and TAF are preferred first-line NUCs due to high potency and high genetic barrier to resistance
• TAF has less renal/bone toxicity than TDF — preferred in patients >60, CKD, or osteoporosis
• PEG-IFN offers the advantage of finite therapy and higher HBsAg loss but is limited by side effects and contraindications
• HCC screening (US +/- AFP q6 months) is indicated in HBsAg+ patients based on risk stratification — HBV causes HCC even WITHOUT cirrhosis
• HBeAg-negative chronic hepatitis (phase 4) is increasingly common (precore/basal core promoter mutants) and requires treatment — do not assume HBeAg-negative patients are all inactive carriers
• Functional cure (HBsAg loss) is the ultimate treatment goal; current NUCs achieve this in <5% at 5 years; novel combination approaches are the most promising path forward

References

1. Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599.
2. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
3. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies. Ann Intern Med. 2017;167(3):173-182.
4. Yuen MF, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035.
5. Gane E, et al. Nucleos(t)ide analogues for chronic hepatitis B: A systematic review. Hepatology. 2022;76(5):1443-1461.

Read this lecture as Markdown